Format

Send to

Choose Destination
Curr Opin Pharmacol. 2017 Aug;35:57-65. doi: 10.1016/j.coph.2017.05.007. Epub 2017 Jun 12.

Inflammation as target in cancer therapy.

Author information

1
IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy.
2
IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy; Università Piemonte Orientale, Novara, Italy.
3
Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic.
4
IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy. Electronic address: paola.allavena@humanitasresearch.it.

Abstract

Cells of the innate immunity infiltrating tumour tissues promote, rather than halt, cancer cell proliferation and distant spreading. Tumour-Associated Macrophages (TAMs) are abundantly present in the tumour milieu and here trigger and perpetrate a state of chronic inflammation which ultimately supports disease development and contributes to an immune-suppressive environment. Therapeutic strategies to limit inflammatory cells and their products have been successful in pre-clinical tumour models. Early clinical trials with specific cytokine and chemokine inhibitors, or with strategies designed to target TAMs, are on their way in different solid malignancies. Partial clinical responses and stabilization of diseases were observed in some patients, in the absence of significant toxicity. These encouraging results open new perspectives of combination treatments aimed at reducing cancer-promoting inflammation to maximize the anti-tumour efficacy.

PMID:
28618326
DOI:
10.1016/j.coph.2017.05.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center